These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 8464491)
1. Properties of an HIV 'vaccine'. Wahren B; Sandström E; Wigzell H Nature; 1993 Apr; 362(6420):505; author reply 505-6. PubMed ID: 8464491 [No Abstract] [Full Text] [Related]
2. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84. DePalma L Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387 [No Abstract] [Full Text] [Related]
3. Vaccine therapy using rgp 160 in early HIV infection. Redfield R; Birx D; Ketter N; Polonis V; Johnson S; Davis C; Smith G; Oster C; Burke D AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1333. PubMed ID: 1361350 [No Abstract] [Full Text] [Related]
4. Current progress in HIV vaccines. Westblom TU; Belshe RB; Gorse GJ Mo Med; 1991 Nov; 88(11):762-5. PubMed ID: 1805131 [No Abstract] [Full Text] [Related]
5. Vaccination with gp160 in HIV. Oyaizu N; Chirmule N; Pahwa S N Engl J Med; 1992 Jan; 326(5):347; author reply 348. PubMed ID: 1728747 [No Abstract] [Full Text] [Related]
6. Vaccination with gp160 in HIV. Stanberry LR; Bernstein DI; Myers MG N Engl J Med; 1992 Jan; 326(5):347-8. PubMed ID: 1728748 [No Abstract] [Full Text] [Related]
7. AIDS vaccine boosts immunity in HIV patients. RN; 1991 Oct; 54(10):103. PubMed ID: 1925340 [No Abstract] [Full Text] [Related]
8. Properties of an HIV 'vaccine'. Volvovitz F; Smith G Nature; 1993 Apr; 362(6420):504-5; author reply 505-6. PubMed ID: 8464490 [No Abstract] [Full Text] [Related]
9. Human trials of AIDS vaccines: current status and future directions. Koff WC; Fauci AS AIDS; 1989; 3 Suppl 1():S125-9. PubMed ID: 2558684 [No Abstract] [Full Text] [Related]
10. MicroGeneSys drops out of NIH trial for AIDS vaccine. Macilwain C Nature; 1993 Mar; 362(6418):277. PubMed ID: 8455703 [No Abstract] [Full Text] [Related]
11. Two additional AIDS vaccines approved for clinical trials. J Am Osteopath Assoc; 1991 May; 91(5):433. PubMed ID: 2061098 [No Abstract] [Full Text] [Related]
12. Production in rabbits of high levels of anti-HIV-1 gp160 antibodies. Relyveld E; Bizzini B Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):389-93. PubMed ID: 7580832 [TBL] [Abstract][Full Text] [Related]
13. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals. Zunich KM; Lane HC; Davey RT; Falloon J; Polis M; Kovacs JA; Masur H AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1335. PubMed ID: 1466952 [No Abstract] [Full Text] [Related]
17. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160. Bona C; Nixon A; Kennedy R; Zaghouani H AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1377. PubMed ID: 1466959 [No Abstract] [Full Text] [Related]